propranolol has been researched along with Hepatocellular Carcinoma in 22 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol." | 7.91 | Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center. ( Öcal, S; Özer Etik, D; Selçuk, H; Suna, N, 2019) |
| " In this study, we investigated the effect of propranolol, a non-selective beta-blocker on overall survival (OS) in unresectable/metastatic hepatocellular carcinoma (HCC) and on recurrence-free survival (RFS) in resectable, curable HCC." | 7.91 | The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. ( Chang, PY; Chang, WC; Chien, WC; Chung, CH; Dai, MS; Ho, CL; Lin, CS; Lin, HH, 2019) |
| "Propranolol bears antioxidant, anti-inflammatory, and antiangiogenic properties and antitumoral effects and therefore is potentially active in the prevention of hepatocellular carcinoma (HCC)." | 7.78 | Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. ( Aout, M; Beaugrand, M; Bourcier, V; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Roulot, D; Trinchet, JC; Vicaut, E, 2012) |
| "Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol." | 3.91 | Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center. ( Öcal, S; Özer Etik, D; Selçuk, H; Suna, N, 2019) |
| " In this study, we investigated the effect of propranolol, a non-selective beta-blocker on overall survival (OS) in unresectable/metastatic hepatocellular carcinoma (HCC) and on recurrence-free survival (RFS) in resectable, curable HCC." | 3.91 | The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. ( Chang, PY; Chang, WC; Chien, WC; Chung, CH; Dai, MS; Ho, CL; Lin, CS; Lin, HH, 2019) |
| "Propranolol bears antioxidant, anti-inflammatory, and antiangiogenic properties and antitumoral effects and therefore is potentially active in the prevention of hepatocellular carcinoma (HCC)." | 3.78 | Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. ( Aout, M; Beaugrand, M; Bourcier, V; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Roulot, D; Trinchet, JC; Vicaut, E, 2012) |
| " In this issue of the journal (beginning on page 1007), Nkontchou and colleagues report their retrospective observational finding that the β-blocker propranolol was associated with a highly statistically significant reduction in the incidence of hepatocellular carcinoma in patients with advanced cirrhosis and related esophageal varices." | 3.78 | Can propranalol prevent hepatocellular carcinoma? ( London, WT; McGlynn, KA, 2012) |
| "Nonselective β-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis." | 3.78 | Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? ( Cho, YK; Chon, CU; Jeon, WK; Kim, BI; Kim, HJ; Kim, TW; Park, DI; Park, JH; Sohn, CI; Won, HS, 2012) |
| "Propranolol treatment decreased the expression of adrenergic receptor β‑2 to a greater extent than adrenergic receptor β‑1, and induced apoptosis in the liver cancer cells." | 1.48 | Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. ( Han, T; Liu, H; Lv, H; Tang, F; Wang, F; Wang, P; Xu, R; Zhang, X; Zhu, Z, 2018) |
| "The new human hepatoma cell line HBG BC2 possesses the capacity of being reversibly differentiated in vitro and of maintaining a relatively higher metabolic rate when in the differentiated state (3 weeks) as compared to HepG2 cells, and thus may allow the conduct of repeated toxicity testing on cells in culture." | 1.32 | A new hepatoma cell line for toxicity testing at repeated doses. ( Arrivet, E; Bichet, N; Fabre, N; Prenez, A; Roome, NO; Trancard, J; Vericat, JA, 2003) |
| "Larger gastric varices have been shown to be the only risk factor for rebleeding (adjusted odds ratio, 4." | 1.31 | Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis. ( Chen, GH; Wu, CY; Yeh, HZ, 2002) |
| "Diltiazem was only stimulatory on 125I-LDL processing in leukocytes." | 1.30 | Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells. ( Behnke, B; Gebhardt, A; Naegele, H; Strohbeck, M, 1998) |
| "Metabolism of propranolol by the human hepatoma cell line Hep G2 was studied." | 1.28 | Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. ( Steiner, A; Walle, T; Walle, UK, 1992) |
| "Verapamil induced an increase in the cellular cholesterol content in preloaded cells." | 1.28 | Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol. ( Auclair, M; Chappey-Gillet, B; Mazière, C; Mazière, JC; Salmon, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bucatariu, SM | 1 |
| Constantin, M | 1 |
| Varganici, CD | 1 |
| Rusu, D | 1 |
| Nicolescu, A | 1 |
| Prisacaru, I | 1 |
| Carnuta, M | 1 |
| Anghelache, M | 1 |
| Calin, M | 1 |
| Ascenzi, P | 1 |
| Fundueanu, G | 1 |
| Cao, M | 1 |
| Huang, W | 1 |
| Chen, Y | 1 |
| Li, G | 1 |
| Liu, N | 1 |
| Wu, Y | 1 |
| Wang, G | 1 |
| Li, Q | 1 |
| Kong, D | 1 |
| Xue, T | 1 |
| Yang, N | 1 |
| Liu, Y | 1 |
| Wang, F | 2 |
| Liu, H | 1 |
| Xu, R | 1 |
| Wang, P | 1 |
| Tang, F | 1 |
| Zhang, X | 1 |
| Zhu, Z | 1 |
| Lv, H | 1 |
| Han, T | 1 |
| Suna, N | 1 |
| Özer Etik, D | 1 |
| Öcal, S | 1 |
| Selçuk, H | 1 |
| Chang, PY | 1 |
| Chung, CH | 1 |
| Chang, WC | 1 |
| Lin, CS | 1 |
| Lin, HH | 1 |
| Dai, MS | 1 |
| Ho, CL | 1 |
| Chien, WC | 1 |
| Jiang, W | 1 |
| Li, Y | 1 |
| Li, ZZ | 1 |
| Sun, J | 1 |
| Li, JW | 1 |
| Wei, W | 1 |
| Li, L | 1 |
| Zhang, C | 1 |
| Huang, C | 1 |
| Yang, SY | 1 |
| Yang, J | 1 |
| Kong, GY | 1 |
| Li, ZF | 1 |
| Iavarone, M | 1 |
| Perrino, M | 1 |
| Viganò, M | 1 |
| Beck-Peccoz, P | 1 |
| Fugazzola, L | 1 |
| Nkontchou, G | 1 |
| Aout, M | 1 |
| Mahmoudi, A | 1 |
| Roulot, D | 1 |
| Bourcier, V | 1 |
| Grando-Lemaire, V | 1 |
| Ganne-Carrie, N | 1 |
| Trinchet, JC | 1 |
| Vicaut, E | 1 |
| Beaugrand, M | 1 |
| London, WT | 1 |
| McGlynn, KA | 1 |
| Kim, TW | 1 |
| Kim, HJ | 1 |
| Chon, CU | 1 |
| Won, HS | 1 |
| Park, JH | 1 |
| Park, DI | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Wu, CY | 1 |
| Yeh, HZ | 1 |
| Chen, GH | 1 |
| Fabre, N | 1 |
| Arrivet, E | 1 |
| Trancard, J | 1 |
| Bichet, N | 1 |
| Roome, NO | 1 |
| Prenez, A | 1 |
| Vericat, JA | 1 |
| Poynard, T | 1 |
| Naveau, S | 1 |
| Poitrine, A | 1 |
| Lebourgeois, P | 1 |
| Hilpert, G | 1 |
| Chaput, JC | 1 |
| Naegele, H | 1 |
| Behnke, B | 1 |
| Gebhardt, A | 1 |
| Strohbeck, M | 1 |
| Narimatsu, S | 1 |
| Kobayashi, N | 1 |
| Asaoka, K | 1 |
| Masubuchi, Y | 1 |
| Horie, T | 1 |
| Hosokawa, M | 1 |
| Ishikawa, T | 1 |
| Ohmori, S | 1 |
| Kitada, M | 1 |
| Miyano, J | 1 |
| Kataoka, H | 1 |
| Yamamoto, S | 1 |
| Okamura, N | 1 |
| Terayama, H | 1 |
| Shwed, JA | 1 |
| Walle, UK | 2 |
| Walle, T | 2 |
| Steiner, A | 1 |
| Chappey-Gillet, B | 1 |
| Salmon, S | 1 |
| Mazière, C | 1 |
| Auclair, M | 1 |
| Mazière, JC | 1 |
| Ohzato, H | 1 |
| Gotoh, M | 1 |
| Monden, M | 1 |
| Okamura, J | 1 |
| Mori, T | 1 |
| Dybing, E | 1 |
| Boyd, H | 1 |
| Louis, CJ | 1 |
| Martin, TJ | 1 |
22 other studies available for propranolol and Hepatocellular Carcinoma
| Article | Year |
|---|---|
A new sponge-type hydrogel based on hyaluronic acid and poly(methylvinylether-alt-maleic acid) as a 3D platform for tumor cell growth.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Diphenhydramine; Hep G2 Cells; Humans; Hy | 2020 |
Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through β-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
Topics: Adrenergic beta-Antagonists; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL5; | 2021 |
Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells.
Topics: Adrenergic beta-Antagonists; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Cycle; Cell Line | 2018 |
Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; | 2019 |
The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male | 2019 |
Chronic restraint stress promotes hepatocellular carcinoma growth by mobilizing splenic myeloid cells through activating β-adrenergic signaling.
Topics: Adrenergic Agents; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemoki | 2019 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, C | 2010 |
Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Human | 2012 |
Can propranalol prevent hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; M | 2012 |
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alcohol Drinking; Carcinoma, Hepatocellular; Female; Follo | 2012 |
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis.
Topics: Adrenergic beta-Antagonists; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gast | 2002 |
A new hepatoma cell line for toxicity testing at repeated doses.
Topics: Acetaminophen; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Dru | 2003 |
Recurrent bleeding and propranolol?
Topics: Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Live | 1983 |
Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells.
Topics: Antihypertensive Agents; Carcinoma, Hepatocellular; Cholesterol; Diltiazem; Humans; Leukocytes, Mono | 1998 |
High-performance liquid chromatographic analysis of the sulfation of 4-hydroxypropranolol enantiomers by monkey liver cytosol.
Topics: Adult; Aged; Animals; Arylsulfotransferase; Carcinoma, Hepatocellular; Chromatography, High Pressure | 2001 |
Comparison of the epinephrine-mediated activation of adenylate cyclase in plasma membranes from liver and ascites hepatomas of rats.
Topics: Adenylyl Cyclases; Animals; Carcinoma, Hepatocellular; Cell Membrane; Enzyme Activation; Epinephrine | 1976 |
Hep G2 cell line as a human model for sulphate conjugation of drugs.
Topics: Arylsulfotransferase; Carcinoma, Hepatocellular; Dopamine; Humans; Liver; Liver Neoplasms; Nitrophen | 1992 |
Induction of propranolol metabolism in the Hep G2 human hepatoma cell line.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Monoamine Oxidase Inhibitors; Oxidation-Reductio | 1992 |
Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol.
Topics: Calcium Channel Blockers; Carcinoma, Hepatocellular; Cholesterol; Humans; Hydrolysis; Lipoproteins, | 1990 |
[Effect of propranolol on intractable ascites following liver resection].
Topics: Adrenergic beta-Antagonists; Ascitic Fluid; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Ci | 1986 |
Effects of membrane stabilizers on glucuronidation and amino acid transport in cultures of rat hepatoma cells.
Topics: Alanine; Aminoisobutyric Acids; Animals; Antipsychotic Agents; Biological Transport; Carcinoma, Hepa | 1973 |
Activity and hormone responsiveness of adenyl cyclase during induction of tumors in rat liver with 3'-methyl-4-dimethylaminoazobenzene.
Topics: Adenylyl Cyclases; Animals; Carcinoma, Hepatocellular; Cell Fractionation; Diet; Enzyme Activation; | 1974 |